Valuation check: OVID's P/E ratio is -5.6, below the Healthcare sector average of 25.3.
Get informed when a big investor buys or sells
+ Follow-5.60
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Ovid Therapeutics (OVID) currently reports a P/E ratio of -5.6. That is below the Healthcare sector average of 25.3. Use the charts on this page to explore Ovid Therapeutics's P/E ratio history and peer comparisons.
Ovid Therapeutics's P/E ratio of -5.6 is lower than the Healthcare sector average of 25.3. That is roughly 122.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Ovid Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -5.6, OVID can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -5.6, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for Ovid Therapeutics, and consider following OVID for alerts when major investors trade the stock.
Ovid Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -5.6 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OVID with unrelated industries.